Systemic sclerosis is a serious autoimmune disease affecting approximately 90,000 people in the United States and Europe and is associated with significant morbidity and up to 60% 10-year mortality. There are currently no drugs specifically […]
The ADVANCE clinical trial is designed to evaluate the safety and protein expression following a single administration of ADVM-043, Adverum’s novel gene therapy candidate. “We are excited to dose the first patient in the ADVANCE […]
January 4, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG), the global biotechnology leader in rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for maribavir (SHP620), […]
The PD-1/PD-L1 ICI class is becoming a new standard of care for patients with advanced NSCLC, demonstrating efficacy versus chemotherapy in first- and second-line treatment. There continue to be no safety concerns, as safety data […]
Allogeneic haematopoietic stem cell transplantation (HSCT) is a curative therapy for patients with life-threating haematological disorders and the most successful cell replacement therapy developed to date with over 40,000 transplantations performed per year worldwide. Cord […]